浏览全部资源
扫码关注微信
雷公藤甲素联合吉非替尼对
EGFR 突变NSCLC细胞的协同效应分析Analysis of the synergistic effect of triptolide combined with gefitinib on
EGFR -mutant NSCLC cells- 中国药房 2023年34卷第18期 页码：2219-2225
- 作者机构：
1.咸宁市中心医院/湖北科技学院附属第一医院呼吸与危重症医学科，湖北 咸宁 437100
2.湖北科技学院临床医学院医学实验实训中心，湖北 咸宁 437100
- 作者简介：
副主任医师。研究方向：慢性阻塞性肺疾病、哮喘、肺炎、肺癌、间质性肺病的基础与临床。E-mail：bichez955393@163.com
主任医师。研究方向：肿瘤内科基础与临床。E-mail：87146788@qq.com
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.18.09
中图分类号： R965纸质出版日期：2023-09-30，
收稿日期：2023-03-02，
修回日期：2023-08-03，
扫 描 看 全 文
张艺,郭芬.雷公藤甲素联合吉非替尼对EGFR突变NSCLC细胞的协同效应分析[J].中国药房,2023,34(18):2219-2225.
ZHANG Yi,GUO Fen.Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells[J].ZHONGGUO YAOFANG,2023,34(18):2219-2225.
张艺,郭芬.雷公藤甲素联合吉非替尼对EGFR突变NSCLC细胞的协同效应分析[J].中国药房,2023,34(18):2219-2225. DOI： 10.6039/j.issn.1001-0408.2023.18.09.
ZHANG Yi,GUO Fen.Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells[J].ZHONGGUO YAOFANG,2023,34(18):2219-2225. DOI： 10.6039/j.issn.1001-0408.2023.18.09.
摘要
目的
2
探讨雷公藤甲素（TPL）联合表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）吉非替尼对
EGFR
突变非小细胞肺癌（NSCLC）细胞的协同效应及潜在机制。
方法
2
体外培养人NSCLC细胞系H1975（
EGFR
T790M/L858R突变的耐药细胞系）和H1299（
EGFR
野生型的非耐药细胞系），采用MTT法检测细胞存活率并通过联合用药指数（CI）评价TPL和吉非替尼的联用效应。将H1975细胞分为空白组，低、高浓度TPL组（5、15 nmol/L），吉非替尼组（2 μmol/L），低浓度TPL+吉非替尼组、高浓度TPL+吉非替尼组（5 nmol/L TPL+2 μmol/L吉非替尼、15 nmol/L TPL+2 μmol/L吉非替尼），采用流式细胞术检测其凋亡及周期分布情况；利用分子对接技术预测TPL与EGFR的结合能力，并采用流式细胞术检测细胞中磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/Akt/mTOR）通路及自噬相关蛋白[微管相关蛋白1轻链3α（MAP1LC3A）、MAP1LC3B]的表达情况。
结果
2
TPL对H1975和H1299细胞的增殖均有一定的抑制作用，且有浓度、时间依赖趋势；5或15 nmol/L TPL联合吉非替尼作用48 h对H1975细胞的增殖均有协同抑制效应（CI＜1），而对H1299细胞则无协同作用（CI＞1）。与空白组比较，各药物组的细胞凋亡率和G
0
/G
1
期细胞的比例均显著升高，S期、G
2
/M期（个别TPL组除外）细胞的比例均显著降低，且联用组效果更优（
P
＜0.05）。分子对接结果显示，TPL的羟基可与
EGFR
T790M/L858R突变编码产物的Thr854残基形成氢键。与空白组比较，各药物组细胞中通路相关蛋白的表达均显著下调，自噬相关蛋白的表达均显著上调，且联用组效果更优（
P
＜0.05）。
结论
2
TPL联合吉非替尼可协同抑制
EGFR
突变NSCLC细胞的增殖活性，其作用机制可能与下调PI3K/Akt/mTOR通路和诱导细胞自噬有关。
Abstract
OBJECTIVE
2
To investigate the synergistic effect of triptolide （TPL） combined with epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） gefitinib on
EGFR
-mutated non-small cell lung cancer （NSCLC） cells and its potential mechanism.
METHODS
2
Human NSCLC cell lines H1975 （
EGFR
T790M/L858R mutated drug-resistant cell lines） and H1299 （
EGFR
wild-type non-drug-resistant cell lines） were cultured
in vitro
. MTT method was used to detect cell activity， and the effect of combined medication was evaluated by the combination index （CI）. The H1975 cells were divided into blank group， low-concentration and high-concentration groups of TPL （5 nmol/L or 15 nmol/L）， gefitinib group （2 μmol/L）， low-concentration and high-concentration groups of TPL+gefitinib （5 nmol/L TPL+2 μmol/L gefitinib， 15 nmol/L TPL+2 μmol/L gefitinib）. Flow cytometry was used to detect the apoptosis of H1975 cells and the distribution of the cell cycle. Molecular docking studies were used to predict the binding ability of TPL to EGFR. The expressions of phosphatidylinositol 3 kinase （PI3K）/protein kinase B （Akt）/mammalian target of rapamycin （mTOR） pathway and autophagy-related proteins [microtubule-associated protein 1 light chain 3α （MAP1LC3A）， MAP1LC3B] in H1975 cells were detected by flow cytometry.
RESULTS
2
TPL had a strong inhibitory effect on the proliferation of H1975 and H1299 cells in a time-dependent and dose-dependent manner. Forty-eight hours treatment of 5 or 15 nmol/L TPL combined with gefitinib had a synergistic inhibitory effect on the proliferation of H1975 cells （CI＜1）， while there was no synergistic inhibitory effect on H1299 cells （CI＞1）. Compared with the blank group， the apoptosis rate and the proportion of H1975 cells at G
0
/G
1
phase were increased significantly in administration groups， while the proportions of cells at S phase and G
2
/M phase （except for several TPL groups） were decreased significantly， and the combination group had better effects （
P
＜0.05）. Molecular docking studies showed that the hydroxyl radical of TPL could form hydrogen bonds with the Thr854 residue of the product encoded by
EGFR
T790M/L858R mutation. Compared with the blank group， the expressions of pathway-related proteins were down-regulated significantly in administration groups， while those of autophagy-related proteins were up-regulated significantly， and the combination group had better effects （
P
＜0.05）.
CONCLUSIONS
2
TPL combined with gefitinib can synergically inhibit the proliferation activity of
EGFR
-mutated NSCLC cells， the mechanism of which may be related to the down-regulation of PI3K/Akt/mTOR pathway and induction of autophagy.
关键词
雷公藤甲素吉非替尼表皮生长因子受体酪氨酸激酶抑制剂非小细胞肺癌磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白通路自噬耐药
Keywords
gefitinibepidermal growth factor receptortyrosine kinase inhibitornon-small cell lung cancerphosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin pathwayautophagydrug resistance
references
LAMB Y N. Osimertinib：a review in previously untreated，EGFR mutation-positive，advanced NSCLC[J]. Target Oncol，2021，16（5）：687-695.
NAGANO T，TACHIHARA M，NISHIMURA Y. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer[J]. Curr Cancer Drug Targets，2019，19（8）：595-630.
DU X J，YANG B W，AN Q L，et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors[J]. Innovation（Camb），2021，2（2）：100103.
LIU L L，XIONG X. Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients[J]. Curr Oncol，2021，29（1）：77-93.
HOU Z Y，TONG X P，PENG Y B，et al. Broad targeting of triptolide to resistance and sensitization for cancer therapy[J]. Biomedecine Pharmacother，2018，104：771-780.
白利平，康向鹏，林立，等. 自噬介导的雷公藤甲素提高西妥昔单抗对SW480细胞治疗效果的实验研究[J]. 中国药理学通报，2019，35（3）：396-402.
TONG X P，JIANG P，LI Y，et al. Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway[J]. Chem Pharm Bull（Tokyo），2019，67（8）：864-871.
SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.
PARK C H，AMARE M，SAVIN M A，et al. Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells[J]. Blood，1980，55（4）：595-601.
刘畅，李振华，阮艳琴，等. 非小细胞肺癌EGFR-TKIs靶向治疗获得性耐药机制及治疗方案研究进展[J]. 临床合理用药杂志，2022，15（1）：176-180.
刘世光，田伶伶，史冬梅，等. 吉非替尼联合重组人血管内皮抑制素治疗EGFR突变非小细胞肺癌的临床效果观察[J]. 解放军医药杂志，2022，34（3）：6-9.
GAO J，ZHANG Y F，LIU X H，et al. Triptolide：pharmacological spectrum，biosynthesis，chemical synthesis and derivatives[J]. Theranostics，2021，11（15）：7199-7221.
LIU J，CHENG H，HAN L，et al. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles[J]. Drug Des Devel Ther，2018，12：3199-3209.
ZHAO G F，HUANG Z A，DU X K，et al. Molecular doc-king studies of traditional Chinese medicinal compounds against known protein targets to treat non-small cell lung carcinomas[J]. Mol Med Rep，2016，14（2）：1132-1138.
XIE C Q，ZHOU P，ZUO J，et al. Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways[J]. Oncol Lett，2016，12（5）：3586-3590.
ZHU W，LI Y H，ZHAO J J，et al. The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking[J]. Ann Med，2022，54（1）：541-552.
MIAO C C，HWANG W，CHU L Y，et al. LC3A-mediated autophagy regulates lung cancer cell plasticity[J]. Autophagy，2022，18（4）：921-934.
GREMKE N，POLO P，DORT A，et al. mTOR-mediated cancer drug resistance suppresses autophagy and gene-rates a druggable metabolic vulnerability[J]. Nat Commun，2020，11（1）：4684.
WU J，ZHAO X G，SUN Q F，et al. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model[J]. Biomedecine Pharmacother，2020，125：109746.
ZHANG Z R，ZHANG M X，LIU H，et al. AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells[J]. J Cell Biochem，2019，120（1）：756-767.
0
浏览量
1
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies